Femasys Inc. (FEMY) Fair Value 2026

FEMY · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-28, Femasys Inc. (FEMY) trades at $3.20. QOC: 5.6/10. Value Trap Risk: 39/100 (LOW). 1/13 models active.

Key Facts

Ticker
FEMY
Price
$3.20
Quality Score
5.6/10
Value Trap Risk
39/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give FEMY?

1 Intrinsic Value Models vs. Current Price ($3.20)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $1.97 -38.4%

All Models Active

All 1 models are displayed above.

What Is Femasys Inc. (FEMY) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Femasys Inc.'s intrinsic value is estimated at $1.97, suggesting the stock is overvalued at its current price of $3.20. With 1 out of 1 models flagging downside (-38.4% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About FEMY?

1 of 13 models are currently active for FEMY. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does FEMY Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, FEMY ranks #46 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Femasys Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is FEMY a Value Trap?

CirclFi's Value Trap algorithm assigns FEMY a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Femasys Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Femasys Inc.'s fundamental quality profile registers 5.6/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every FEMY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across FEMY's 1 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Femasys Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

LUCYLucyd, IncQOC 5.6ZTEKZentek Ltd.QOC 5.4NYXHNyxoah SAQOC 5.6PLSEPulse Biosciences, Inc.QOC 5.3CUPRCuprina Holdings (Cayman) LimitedQOC 5.6DXRDaxor CorporationQOC 4.6ATRAptarGroup, Inc.QOC 8.9MDLNMedline Inc.QOC 7.7MMEDMiniMed Group, Inc.QOC 6.3ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: LUCY · ZTEK · NYXH · PLSE · CUPR · DXR · ATR · MDLN · MMED · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to FEMY?

7 companies across all industries closest to FEMY’s Quality of Company score of 5.6/10.

URGUr-Energy Inc.QOC 5.6YYGHYY Group Holding LimitedQOC 5.6EQEquillium, Inc.QOC 5.6KARXKarbon-X Corp.QOC 5.6BHMBluerock Homes Trust, Inc.QOC 5.6VHCVirnetX Holding CorporationQOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: URG · YYGH · EQ · KARX · BHM · VHC · NVDA

Where Does FEMY Sit in CirclFi's Medical Instruments & Supplies Rankings?

FEMY is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Femasys Inc.’s Valuation?

What is Femasys Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Femasys Inc. (FEMY). The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is FEMY overvalued or undervalued right now?

At $3.20, 0 of 1 active models suggest FEMY may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Femasys Inc.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 5.6 mean for FEMY?

Femasys Inc.'s QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on FEMY?

CirclFi analyzes FEMY with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is FEMY a value trap in 2026?

Femasys Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Femasys Inc. (FEMY) a Quality of Company score of 5.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/FEMY/ · Methodology
Primary sources for this FEMY valuation
  • Financial statements: Femasys Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001339005) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for FEMY as of ; valuations recomputed .